BACKGROUND: Chronic inflammation has been implicated in the pathogenesis of several cancers, including lung and laryngeal cancer. The objective of the study is to elucidate the association between ICS use and diagnosis of lung and laryngeal cancer. METHODS: A nested case-control study based on the Korean national claims database included new adult users of inhaled medications between January 1, 2007, and December 31, 2010. Patients diagnosed with lung cancer or laryngeal cancer after enrollment were identified as cases and up to five control individuals matched for age, sex, diagnosis of asthma or COPD, Charlson Comorbidity Index scores, number of health care visits, and initiation date were selected. RESULTS: From the 792,687 eligible cohort, 9177 individuals diagnosed with lung cancer were matched with 37,048 controls. Additionally, 408 laryngeal cancer patients and 1651 controls were matched. ICS use was associated with a decreased rate of lung cancer diagnosis [adjusted odds ratio (aOR), 0.79; 95% confidence interval (CI), 0.69-0.90]. The inverse association between ICS use and lung cancer risk was dose dependent (P < 0.0001 for the trend). However, no reduction in the risk of laryngeal cancer among ICS users was identified (aOR, 1.06; 95% CI, 0.62-1.18). CONCLUSION: The use of ICS is associated with a reduced risk of lung cancer but not of laryngeal cancer.
BACKGROUND: Chronic inflammation has been implicated in the pathogenesis of several cancers, including lung and laryngeal cancer. The objective of the study is to elucidate the association between ICS use and diagnosis of lung and laryngeal cancer. METHODS: A nested case-control study based on the Korean national claims database included new adult users of inhaled medications between January 1, 2007, and December 31, 2010. Patients diagnosed with lung cancer or laryngeal cancer after enrollment were identified as cases and up to five control individuals matched for age, sex, diagnosis of asthma or COPD, Charlson Comorbidity Index scores, number of health care visits, and initiation date were selected. RESULTS: From the 792,687 eligible cohort, 9177 individuals diagnosed with lung cancer were matched with 37,048 controls. Additionally, 408 laryngeal cancerpatients and 1651 controls were matched. ICS use was associated with a decreased rate of lung cancer diagnosis [adjusted odds ratio (aOR), 0.79; 95% confidence interval (CI), 0.69-0.90]. The inverse association between ICS use and lung cancer risk was dose dependent (P < 0.0001 for the trend). However, no reduction in the risk of laryngeal cancer among ICS users was identified (aOR, 1.06; 95% CI, 0.62-1.18). CONCLUSION: The use of ICS is associated with a reduced risk of lung cancer but not of laryngeal cancer.
Authors: Dena Zeraatkar; Juan P de Torres; Tyler Pitre; Michel Kiflen; Terence Ho; Luis M Seijo Journal: BMC Pulm Med Date: 2022-07-17 Impact factor: 3.320
Authors: Ruyi Huang; Yongyue Wei; Rayjean J Hung; Geoffrey Liu; Li Su; Ruyang Zhang; Xuchen Zong; Zuo-Feng Zhang; Hal Morgenstern; Irene Brüske; Joachim Heinrich; Yun-Chul Hong; Jin Hee Kim; Michele Cote; Angela Wenzlaff; Ann G Schwartz; Isabelle Stucker; John Mclaughlin; Michael W Marcus; Michael P A Davies; Triantafillos Liloglou; John K Field; Keitaro Matsuo; Matt Barnett; Mark Thornquist; Gary Goodman; Yi Wang; Size Chen; Ping Yang; Eric J Duell; Angeline S Andrew; Philip Lazarus; Joshua Muscat; Penella Woll; Janet Horsman; M Dawn Teare; Anath Flugelman; Gad Rennert; Yan Zhang; Hermann Brenner; Christa Stegmaier; Erik H F M van der Heijden; Katja Aben; Lambertus Kiemeney; Juan Barros-Dios; Monica Pérez-Ríos; Alberto Ruano-Ravina; Neil E Caporaso; Pier Alberto Bertazzi; Maria Teresa Landi; Juncheng Dai; Hongbing Hongbing Shen; Guillermo Fernandez-Tardon; Marta Rodriguez-Suarez; Adonina Tardon; David C Christiani Journal: EBioMedicine Date: 2015-11 Impact factor: 8.143
Authors: Stefan Prekovic; Karianne Schuurman; Isabel Mayayo-Peralta; Anna G Manjón; Mark Buijs; Selçuk Yavuz; Max D Wellenstein; Alejandro Barrera; Kim Monkhorst; Anne Huber; Ben Morris; Cor Lieftink; Theofilos Chalkiadakis; Ferhat Alkan; Joana Silva; Balázs Győrffy; Liesbeth Hoekman; Bram van den Broek; Hans Teunissen; Donna O Debets; Tesa Severson; Jos Jonkers; Timothy Reddy; Karin E de Visser; William Faller; Roderick Beijersbergen; Maarten Altelaar; Elzo de Wit; Rene Medema; Wilbert Zwart Journal: Nat Commun Date: 2021-07-16 Impact factor: 14.919